טוען...
Body composition and aspirin dose for colorectal adenoma prevention in a randomized clinical trial
BACKGROUND: Visceral adiposity is a risk factor for colorectal adenomas, and aspirin is an established chemopreventive agent. Evidence from clinical trials suggests the effectiveness of aspirin at preventing cardiovascular disease and cancer may require higher doses for higher body weight. METHODS:...
שמור ב:
| הוצא לאור ב: | Cancer Epidemiol Biomarkers Prev |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6608598/ https://ncbi.nlm.nih.gov/pubmed/31263057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-19-0205 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|